PHARMACOKINETICS OF IP CISPLATIN IN REFRACTORY OVARIAN-CARCINOMA

  • 1 January 1983
    • journal article
    • research article
    • Vol. 67  (12) , 1085-1092
Abstract
Four patients with small residual ovarian carcinoma following treatment with cisplatin, doxorubicin and cyclophosphamide subsequently received 57 courses of i.p. cisplatin. Cisplatin (120-270 mg in 2 l Ringer''s lactate) was administered via Tenckhoff catheter, with a dwell time of 15-20 min. Courses were given weekly for 12 wk, with response documented by laparoscopy or laparotomy prior to and following the trial. With a dwell time of 20 mins, 75% .+-. 5% (mean .+-. SD) of Pt was recovered. With 120 mg of cisplatin and a dwell time of 20 min, total plasma Pt peaked at 1.23 .+-. 0.42 .mu.g/ml and by 8 h decreased to 0.67 .+-. 0.12 .mu.g/ml. Filterable (non-protein-bound) Pt peaked at 0.73 .+-. 0.21 .mu.g/ml and by 8 h fell to 0.03 .mu.g/ml. Excretion rate paralleled the filterable plasma curve, peaking at 40 mins; 30% .+-. 7% of absorbed drug was recovered in urine within 24 h. Renal clearance of filterable Pt was 106 .+-. 20 ml/min. Creatinine clearance was 76 .+-. 7 ml/min. Three responses, 1 complete and 2 partial, were noted. Zero to two episodes of vomiting occurred in each course. One patient had a creatinine clearance decrease to 40 ml/min, 1 had 2 episodes of thrombocytopenia and 1 had mild abdominal pain with a cisplatin dose of .gtoreq. 210 mg. No neurotoxicity, catheter infection or peritonitis was encountered.

This publication has 1 reference indexed in Scilit: